Abstract |
Trilostane, a 3beta-hydroxysteroid dehydrogenase inhibitor, has been used successfully over the last few years for the treatment of canine pituitary-dependent hyperadrenocorticism. In a prospective study of 19 dogs with pituitary-dependent hyperadrenocorticism, the adrenal glands were measured before and at least 6 months after initiation of trilostane therapy. Right adrenal gland length and caudal pole thickness and left adrenal gland caudal pole thickness increased significantly (p < or = 0.05); there was no significant change in left adrenal gland length. Enlargement of adrenal glands during trilostane therapy may occur as a result of suppression of the negative feedback mechanism affecting cortisol production.
|
Authors | Panagiotis Mantis, Christopher R Lamb, Angela L Witt, Reto Neiger |
Journal | Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
(Vet Radiol Ultrasound)
2003 Nov-Dec
Vol. 44
Issue 6
Pg. 682-5
ISSN: 1058-8183 [Print] England |
PMID | 14703251
(Publication Type: Evaluation Study, Journal Article)
|
Chemical References |
- Enzyme Inhibitors
- Dihydrotestosterone
- 3-Hydroxysteroid Dehydrogenases
- trilostane
|
Topics |
- 3-Hydroxysteroid Dehydrogenases
(antagonists & inhibitors)
- Administration, Oral
- Adrenal Glands
(diagnostic imaging, drug effects)
- Adrenocortical Hyperfunction
(drug therapy, veterinary)
- Animals
- Dihydrotestosterone
(analogs & derivatives, pharmacology, therapeutic use)
- Dog Diseases
(diagnostic imaging, drug therapy, pathology)
- Dogs
- Enzyme Inhibitors
(pharmacology, therapeutic use)
- Female
- Male
- Prospective Studies
- Treatment Outcome
- Ultrasonography
|